Cambrex, the East Rutherford-based small molecule therapeutics company, has completed the expansion of a facility in Scotland, it announced Monday.
The company said in a news release that the solid form screening and crystallization process development facility in Edinburgh has doubled its footprint, to 15,000 square feet, including an additional 3,500 square feet of laboratory space and a refurbishment of the existing space.
“We have seen an increase in demand for services, and specifically for larger-scale crystallization projects, so this expansion increases our efficiency and ability to respond to these requests,” CEO Tom Loewald said in a prepared statement. “The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases our flexibility to work on projects at all stages of drug development.”
The site currently has 50 employees, and the expansion will enable the company to recruit as many as 40 more.
Financial details were not disclosed.
